Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. Building on proprietary reprogramming technologies and backed by leading investors, Asgard is establishing a pipeline of off-the-shelf gene therapy products designed to induce efficient and personalized immune responses
Our lead program, AT-108, is a first-in-class, off-the-shelf gene therapy that directly reprograms tumor cells into a rare subset of dendritic cells critical for mounting efficient cytotoxic T cell responses, cDC1 cells (conventional dendritic cells type 1). Reprogramming forces the tumor cells to present their tumor antigens, leading to a personalized anti-tumor immune response. It is based on a replication-deficient adenoviral vector that delivers three proprietary reprogramming factors into tumor cells, rewiring them to become antigen-presenting cDC1-like cells.
Asgard is currently preparing for clinical trials of AT-108 by progressing IND-enabling studies and CMC development. Key proof-of-concept data on AT-108 were published in the journal Science in 2024.
